Clinic
ST Anthony's Hospital Association
ST Anthony's Hospital Association was paid $2.98M by Medicaid between Jan 2018 and Dec 2024, across 112 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 9.9% of everything it billed.
33Billing provider infoST ANTHONY'S HOSPITAL ASSOCIATION
MORRILTON, AR 72110
MORRILTON, AR 72110
33aNPI1891778049assigned 11/22/2005
33bProvider typeRural Health Clinic/Center
28Total paid$2.98M
24GClaims152,478
24DCodes billed112
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rural Health Clinic/Center providers in Arkansas
Rank by total paid#2 of 78
Median peer was paid$33K
This provider vs. median91×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 24,495 | $422K | |
| 2019 | 26,397 | $519K | |
| 2020 | 23,474 | $472K | |
| 2021 | 22,118 | $461K | |
| 2022 | 22,191 | $503K | |
| 2023 | 20,186 | $358K | |
| 2024incomplete | 13,617 | $241K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 9.9% | 8,139 | 6,216 | $294K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 9.1% | 1,403 | 1,171 | $271K |
| 70450 | Computed tomography, head or brain; without contrast material | 8.4% | 1,873 | 1,551 | $249K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 8.1% | 2,447 | 2,045 | $240K |
| 80053 | Comprehensive metabolic panel | 7.0% | 10,990 | 8,667 | $207K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 5.0% | 1,036 | 794 | $147K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.4% | 13,083 | 9,646 | $100K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.3% | 1,182 | 1,024 | $99K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.3% | 2,957 | 2,212 | $98K |
| 83880 | 2.6% | 1,818 | 1,449 | $76K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.5% | 4,434 | 3,311 | $74K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.4% | 2,506 | 525 | $72K |
100 more codes
| 99284 | Emergency room visit (serious) | 2.4% | 2,941 | $70K |
| 84484 | 1.8% | 3,999 | $54K | |
| 99285 | Emergency room visit (most serious) | 1.6% | 2,900 | $48K |
| 71045 | Radiologic examination, chest; single view | 1.6% | 3,532 | $46K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.5% | 308 | $45K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 1,773 | $43K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.4% | 201 | $42K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 5,096 | $40K |
| 11043 | 1.3% | 315 | $39K | |
| 36415 | Collection of venous blood by venipuncture | 1.2% | 6,378 | $37K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.1% | 1,041 | $33K |
| 83690 | <1% | 2,956 | $29K | |
| 87430 | <1% | 2,431 | $28K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,853 | $28K |
| 82550 | <1% | 1,753 | $26K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,557 | $25K |
| 81001 | <1% | 5,554 | $24K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,817 | $24K |
| 83735 | <1% | 2,822 | $24K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,663 | $21K |
| 80305 | <1% | 1,675 | $21K | |
| 81025 | <1% | 2,403 | $20K | |
| 87077 | <1% | 1,697 | $19K | |
| 83605 | <1% | 1,215 | $19K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 481 | $16K |
| 87081 | <1% | 1,680 | $15K | |
| 80061 | Lipid panel | <1% | 2,009 | $14K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,220 | $14K |
| 85730 | <1% | 1,572 | $12K | |
| 82553 | <1% | 1,116 | $12K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 137 | $12K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,152 | $11K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 49 | $10K |
| 87186 | <1% | 1,933 | $9K | |
| 85610 | <1% | 2,250 | $9K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 663 | $9K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,076 | $8K |
| 87040 | <1% | 880 | $8K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,082 | $7K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 3,264 | $6K |
| 82962 | <1% | 767 | $6K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,390 | $4K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,045 | $4K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 203 | $4K |
| 87070 | <1% | 348 | $4K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 117 | $4K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 79 | $3K |
| 81000 | <1% | 962 | $3K | |
| 81003 | <1% | 1,512 | $3K | |
| 97032 | <1% | 138 | $3K | |
| 85027 | <1% | 660 | $2K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 19 | $2K |
| 86677 | <1% | 63 | $2K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 138 | $2K |
| 86317 | <1% | 91 | $2K | |
| 87428 | <1% | 43 | $2K | |
| 82803 | <1% | 22 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 732 | $1K |
| 73610 | <1% | 67 | $1K | |
| 73630 | <1% | 44 | $1K | |
| 80050 | General health panel | <1% | 24 | $1K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 23 | $961.77 |
| 85379 | <1% | 72 | $919.81 | |
| 84481 | <1% | 104 | $827.29 | |
| 82607 | <1% | 121 | $690.36 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 14 | $665.09 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 185 | $634.10 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 32 | $593.04 |
| 73564 | <1% | 14 | $583.23 | |
| 81002 | <1% | 46 | $552.28 | |
| 74022 | <1% | 15 | $448.00 | |
| 84439 | <1% | 80 | $399.30 | |
| 80320 | <1% | 26 | $361.92 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 578 | $340.57 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 385 | $308.91 |
| G2025 | Payment for a telehealth distant site service furnished by a rural health clinic (rhc) or federally qualified health center (fqhc) only | <1% | 33 | $296.18 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,372 | $255.92 |
| 82248 | <1% | 32 | $213.06 | |
| 0001A | <1% | 38 | $205.53 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 12 | $140.00 |
| 81015 | <1% | 141 | $138.03 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 451 | $126.58 |
| 80076 | <1% | 12 | $105.03 | |
| 94664 | <1% | 74 | $101.03 | |
| 87205 | <1% | 18 | $80.95 | |
| 83540 | <1% | 40 | $61.82 | |
| J2704 | Injection, propofol, 10 mg | <1% | 282 | $58.46 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 58 | $49.48 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 30 | $45.23 |
| A9270 | Non-covered item or service | <1% | 2,106 | $36.80 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 30 | $35.67 |
| 84436 | <1% | 16 | $17.80 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 75 | $4.38 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 57 | $2.67 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 16 | $0.92 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 31 | $0.40 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 21 | $0.02 |
| 83550 | 0% | 13 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 26 | $0.00 |
| 99401 | 0% | 23 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSTEARNES, BOB (DIRECTOR REVENUE CYCLE)